INTRODUCTION
Models of simian immunodeficiency virus (SIV) infection and simian human immunodeficiency virus (SHIV) infection in macaques are widely used. SIVmac239/251 is a CCR5-tropic virus that infects activated CD4 + T cells. Chimeric simian human immunodeficiency virus SHIV89.6P is a highly pathogenic dual-tropic virus that causes rapid elimination of CD4 + T cells within 2 weeks of infection (Evans & Silvestri, 2013; Feinberg & Moore, 2002) . Most of the studies on development of an AIDS vaccine have been carried out using rhesus macaques of Indian origin because the extensive knowledge on Indian rhesus macaques has allowed detailed characterization of MHC-restricted immune responses elicited during SIV infection (Allen et al., 2001; Loffredo et al., 2007; Moth e et al., 2002; 2003) . Moreover, as is the case for humans, mucosal transmission was observed in rhesus macaques exposed intrarectally or intravaginally to a low dose of SIV or SHIV (Keele et al., 2009; Varela et al., 2011) . This mucosal model of SIV infection is a valuable tool for the evaluation of potential vaccine regimens (Wilson et al., 2006) . Thus, models of SIV infection in non-human primates are important for the analysis of AIDS pathogenesis and the efficacy of a human immunodeficiency virus (HIV) vaccine or therapeutic HIV interventions.
The cynomolgus macaque (Macaca fascicularis) is one of the non-human primates most commonly used in biomedical research worldwide (Carlsson et al., 2004) . Cynomolgus macaques are more readily available than rhesus macaques and have become a useful model for human infectious diseases, including AIDS (Antony & MacDonald, 2015) , severe acute respiratory syndrome (Smits et al., 2011) and influenza (Nakayama et al., 2013) , to evaluate therapeutic and prophylactic strategies. Previous studies showed that the pathogenicity of both SIVmac251 and SHIV89.6P is markedly attenuated in cynomolgus macaques compared to that in Indian rhesus macaques. Manifestations of attenuated pathogenicity included lower levels of plasma viraemia, preservation of CD4 + T-cell number, preservation of both cellular and humoral immune responses, and increased survival time (Reimann et al., 2005) . However, the macaques used in those studies were all of Mauritian origin. The pathogenicities of these viruses may be different in cynomolgus macaques from different Asian locations.
Tsukuba Primate Research Center (TPRC) in Japan has a large-scale breeding colony of experimental cynomolgus macaques, which play a significant role in the development of pharmaceutical products and medical technologies. The cynomolgus macaques in TPRC were obtained from Indonesia, Malaysia and Philippines (Honjo, 1985) . TPRC established a new breeding system in 1980 for the purpose of genetic control. The cynomolgus macaques have therefore been bred as pure blood of each origin without interbreed crossing (Honjo et al., 1984) . In addition, several micro-organisms, including bacteria, parasites and viruses, were eliminated from the cynomolgus macaque colony in TPRC. Various kinds of viruses (B virus, measles virus, simian varicella virus, SIV, simian Tcell leukaemia virus, simian D type retrovirus, simian cytomegalovirus, simian Epstein-Barr virus and simian foamy virus), bacteria (Shigella, Salmonella and Mycobacteria spp.) and an intestinal helminth were chosen as target microorganisms to establish a specific pathogen-free colony (Yasutomi, 2010) . Such pure-blood macaques are important regarding comparison of various genetic factors in biological studies including studies aimed at HIV vaccine development. However, SIV or SHIV infectivity and pathogenesis in cynomolgus macaques from different Asian countries remain to be clarified.
A previous study on characterization of MHC class I in cynomolgus macaques of Indonesian origin suggested that the Mafa-B*7601 allele might have been associated with SIV replication (Pendley et al., 2008) . The goal of this study was the establishment of an AIDS model using cynomolgus macaques of Asian origin, including the Philippines, Malaysia and Indonesia, which exhibited genetically diverse populations. To address this issue, we performed a longitudinal analysis of pathogenicity and evaluated virus-specific immunity induced by infection with the pathogenic virus SIVmac239 and the acutely pathogenic virus SHIV89.6P in the macaques. We also examined viral replication and immune responses in the cynomolgus macaques infected with SIVmac239, SIVmac251 or SHIV89.6P intrarectally.
The results provide a useful macaque model for HIV vaccine preclinical studies.
RESULTS
High levels of plasma viral load during SIVmac239 and SHIV infection in cynomolgus macaques of Asian country origins Sixteen cynomolgus macaques were infected intravenously with SIVmac239 and SHIV89.6P (Table 1) . MHC class I alleles and Trim5a genotypes in inoculated macaques are shown in Table 1 . Plasma viral loads were monitored periodically using quantitative RT-PCR. Peak plasma viral loads in macaques were observed about 2 or 3 weeks after SIVmac239 and SHIV89.6P infection. Exceptionally, peak viraemia in one animal (#0055) was almost 10 9 copies ml À1 . The highest titre in any animal was about 10 7 copies ml
À1
( Fig. 1a) . Plasma viral loads in two of the four macaques (#0052 and #0053) infected with one TCID 50 of SIVmac239 were maintained at 10 5 -10 6 copies ml À1 after the acute phase of infection (Fig. 1a) . The other macaques (#0051 and #0054) were not infected. Five of the seven macaques infected with 1000 TCID 50 of SIVmac239 showed persistent viraemia with more than 10 4 -10 6 copies ml À1 of viral RNA after the acute phase of infection (Fig. 1a) . In contrast, in the other two macaques (#0061 and #0062), the plasma viral loads were less than 10 4 copies ml À1 at 50 weeks after infection. All of the macaques infected with 10 000 TCID 50 of SHIV89.6P showed stable viraemia above 10 4 -10 7 copies ml À1 of viral RNA after the acute phase of infection (Fig. 1a) .
To determine whether the infected cynomolgus macaques had different viral levels in their lymphoid tissues at 34 weeks post-infection, we investigated the presence of SIV Nef antigen as a marker of virus infection by immunohistochemistry and performed quantitative analysis of proviral SIV DNA. SIV Nef-positive cells were detected in lymphoid tissues in the majority of both SIV-and SHIV-infected macaques (Fig. 1b) . Moreover, most of those infected macaques showed high proviral DNA loads (>1000 copies µg À1 ) in the lymphoid tissues examined (Fig. 1c) . However, two macaques (#0061 and #0062) showed comparably low proviral DNA loads in the tissues, and proviral DNA loads were undetectable in two other macaques (#0051 and #0054).
Disease progression in cynomolgus macaques infected with SIVmac239 and SHIV89.6P
The clinical outcomes for SIV-and SHIV-infected macaques are summarized in Table 2 . These macaques were euthanized when they showed symptoms of AIDS. Eight macaques showed progression of SIV infection to an AIDSlike illness from 658 to 1626 days post-inoculation (Table 2) . Among those eight macaques, animals with low levels of viraemia (#0061 and #0062) also showed symptoms of AIDS. Only one macaque (#0056) did not show symptoms of AIDS. Four of the five macaques infected with SHIV89.6P also showed AIDS symptoms at 399-1250 days post-inoculation (Table 2) . One macaque (#5014), which exhibited a high set point of plasma viral loads, was a rapid progressor ( Fig. 1a and Table 2 ). The remaining macaque (#5002) did not show progression to obvious AIDS-like disease.
CD4 + T cells are rapidly lost in peripheral blood after SHIV infection in cynomolgus macaques
To examine the kinetics of peripheral blood CD4 + T cells in macaques after SIVmac239 and SHIV89.6P infection, we counted CD4 + T cells by flow cytometry. Prior to virus infection, the number of CD4 + T cells in peripheral blood was between 649 and 2487 µl
À1
. We observed a transient decline of CD4 + T cells in macaques infected with SIVmac239, followed by recovery to the baseline level and then a gradual decline (Fig. 2a) . When those macaques showed AIDS symptoms, the count of CD4 + T cells in peripheral blood was between 20 and 650 µl
. In contrast, infection with SHIV89.6P dramatically reduced CD4 + T cells in macaques. The SHIV89.6P-infected macaques showed very low CD4 + T-cell counts (<50 cells µl
) during the observation period (Fig. 2a) .
In addition to the evaluation of CD4 + T cells in blood, we examined CD4 + T cells in lymphoid tissues from the SIVmac239-or SHIV89.6P-infected macaques at 34 weeks Fig. 2(b) . In uninfected macaques, CD4 + T lymphocytes were homogeneously distributed in the paracortical and medullary regions. In contrast, SIVmac239-infected macaques showed a reduction of CD4 + T lymphocytes in the paracortical regions of lymph nodes. It is notable that the numbers of CD4 + T cells were greatly reduced in the paracortical and medullary regions in SHIV89.6P-infected macaques (Fig. 2b) . To confirm the observed cell reduction in inguinal lymphoid tissue, we examined the proportion of CD4 + T cells in lymphoid tissue by flow cytometry. In lymphoid tissues of uninfected macaques, the proportions of CD4 + T cells were 70.9 and 62.4 % (Fig. 2c ). In addition, the mean proportion of CD4 + T cells in four naïve macaques was 67.6±5.7 % (data not shown). On the other hand, the proportion of CD4 + T cells in SIVmac239-infected macaques was 42.9±7.9 %, and the SHIV89.6P-infected macaques showed a severe depletion of CD4 + T cells (1.8±2.9 %) ( Fig. 2c) , consistent with the results of immunohistochemistry.
Humoral and cellular immune responses against SIV or SHIV antigen in infected cynomolgus macaques
We analysed the immune response elicited in macaques after viral infection by determining both humoral and cellular immune responses to the inoculated viruses. SIV-or SHIVspecific antibody titres in plasma of SIVmac239-and SHIV89.6P-infected macaques were examined using a passive agglutination method. In SIVmac239-infected macaques, antibodies against SIV were detected at 4 weeks postinfection, and the macaques then developed strong antibody responses (Fig. 3a) . Moreover, in macaques infected with SIVmac239, SIV Gag-specific antibodies as well as anti-SIV virion antibodies were detected in plasma (data not shown). An antibody response was not seen in the uninfected macaques (#0051 and #0054). On the other hand, SHIV89.6P-infected macaques had low titres of antibody at 4-12 weeks post-infection (Fig. 3b) . Anti-SHIV antibody titres in plasma then gradually increased up to 120 weeks post-infection. However, one of the SHIV89.6P-infected macaques (#5014) showed no antibody response. 
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Next, we analysed the induction of cellular immunity by detecting viral antigen (SIV Gag-Pol and SIV Env or HIV Env)-specific IFN-g ELISPOT responses in PBMCs at 16, 50 and 90 weeks after infection. The macaques infected with SIVmac239 showed ELISPOT responses against viral antigens at 16 weeks post-infection (Fig. 3c) . The ELISPOT responses increased in six macaques at later time points, whereas the ELISPOT responses were marginal in three macaques (#0060, #0061 and #0062). At 90 weeks post-infection, ELISPOT responses were reduced in most of the macaques infected with SIVmac239. ELISPOT responses were not detected in uninfected macaques (#0051 and #0054). On the other hand, ELISPOT responses against SHIV89.6P were detected in three macaques (#5002, 5007 and #5023) at 16 weeks and were slightly increased at 50 weeks post-infection (Fig. 3d) . The other macaques (#5014 and #5024) infected with SHIV89.6P showed weak ELISPOT responses at all time points.
Repeated mucosal low-medium-or high-dose challenge of SIVmac239, SIVmac251 or SHIV89.6P
We analysed 20 cynomolgus macaques infected intrarectally with a repeated low, medium or high dose of SIVmac239, SIVmac251 or SHIV89.6P. Two macaques in the first group were repeatedly inoculated with 50 000, 5000 or 500 TCID 50 of SIVmac239. Two macaques in the second group were repeatedly inoculated with 3000, 300 or 30 TCID 50 of SIVmac251. Two macaques in the third group were repeatedly inoculated with 50 000, 5000, 500 or 50 TCID 50 of SHIV89.6P (Table 3) . MHC class I alleles and Trim5a genotypes in inoculated macaques are shown in Table 3 . Viral RNA was detected in plasma from macaques infected with 50 000 and 5000 TCID 50 of SIVmac239 (Fig. 4a ). Viral RNA was also detectable in plasma from the four macaques infected with 3000 and 300 TCID 50 of SIVmac251 (Fig. 4a) . One of the two macaques inoculated with 30 TCID 50 of SIVmac251 showed a detectable level of viral RNA. Viral RNA was detected in macaques infected with 50 000, 5000 and 500 TCID 50 of SHIV89.6P (Fig. 4a) . From these results, the intrarectal macaque infectious doses were estimated to be 5000, 300 and 500 TCID 50 for SIVmac239, SIVmac251 and SHIV89.6P, respectively.
After repeated inoculation with a low, medium or high dose of SIVmac239 or SIVmac251, the number of CD4 + T cells was maintained at the normal level in both infected and uninfected macaques (Fig. 4b) . The macaques infected with 5000 and 50 000 TCID 50 of SHIV89.6P showed a massive depletion of CD4 + T cells within 6 weeks after infection (Fig. 4b) . In contrast, CD4 + T-cell counts decreased slightly in macaques infected with 500 TCID 50 of SHIV89.6P. 
Humoral and cellular immune responses to SIV or SHIV intrarectal infection
To determine whether the macaques inoculated repeatedly with a low, medium or high dose elicited antibody responses, we examined the kinetics of SIV-or SHIV-specific antibody titres in the plasma of SIVmac239-, SIVmac251-and SHIV89.6P-infected macaques using a passive agglutination method. In SIVmac239-and SIVmac251-infected macaques, antibodies against SIV were detected at 4-8 weeks post-infection and the macaques then developed strong antibody responses (Fig. 5a, b) . SHIV89.6P-infected macaques had low antibody titres at 4-12 weeks post-infection (Fig. 5c) . SIV-or SHIV-specific antibody responses were not seen in the uninfected macaques.
Next, we examined SIV or SHIV antigen (SIV Gag-Pol and SIV Env or HIV Env)-specific IFN-g ELISPOT responses of PBMCs from SIVmac239-, SIVmac251-and SHIV89.6P-inoculated macaques at 12 weeks post-infection. The macaques inoculated with SIVmac239 (#0027, #0029, #0030 and #0031) and SIVmac251 (#0034, #0035, #0036, #0037 and #0039) showed ELISPOT responses against viral antigens at 12 weeks post-infection (Fig. 5d, e) . Weak ELISPOT responses against SHIV89.6P were detected in SHIV89.6P-inoculated macaques (#5041, #5042, #5043, #5044, #5045 and #5046) (Fig. 5f ). ELISPOT responses were not detected in uninfected macaques (#0032, #0033, #0038, #5047 and #5048).
DISCUSSION
Old World macaques are becoming widely used as an invaluable model for studies on the pathogenesis of immunodeficiency virus. However, the characteristics of simian retrovirus infection in cynomolgus macaques have not been comprehensively defined. In an effort to determine whether the cynomolgus macaque can serve as a useful animal model for AIDS vaccine study, we evaluated the infectivity and pathogenesis of SIVmac and SHIV89.6P in cynomolgus macaques of Indonesian, Malaysian or Philippine origin. To our knowledge, this is the first report presenting results of a comparative study in cynomolgus macaques from Asian countries infected with SIVmac239 or SHIV89.6P.
In previous studies, it was found that rhesus macaques of geographically distinct origins show significantly different responses to SIV or SHIV infection (Ling et al., 2002; Reimann et al., 2005) , suggesting that geographically related genetic differences may play roles in determining how susceptible animals are to SIV or SHIV infection. In the present study, high plasma viral loads were similarly observed at 2 weeks post-infection with SIV or SHIV in cynomolgus macaques from Indonesia, Malaysia and Philippines. Also, the high levels of plasma viral loads in those macaques were maintained at a set point. Additionally, in peripheral lymph nodes, high levels of proviral DNA were detected in lymphoid tissues of SIV-or SHIV-infected macaques. Moreover, most of the SIVmac239-and SHIV89.6P-infected macaques were killed due to AIDS symptoms. These results suggest that SIV or SHIV was highly replicative post-infection in cynomolgus macaques, despite the difference in country of origin. #0051  #5002  #5007  #5014  #5023  #5024   #0052  #0053  #0054  #0055  #0056  #0057  #0059  #0060  #0061  #0062   #0051  #0052  #0053  #0054  #0055  #0056  #0057  #0059  #0060  #0061  #0062   #5002   #5007   #5014   #5023   #5024   #5002   #5007   #5014   #5023   #5024   #5002   #5007   #5023   #5024   #0051  #0052  #0053  #0054  #0055  #0056  #0057  #0059  #0060  #0061  #0062   #0051  #0052  #0053  #0054  #0055  #0056  #0057  #0059  #0060  #0061 SHIV strains were shown to cause a substantial CD4 + T-cell depletion in rhesus macaques within a few weeks after infection (Reimann et al., 1999) . In contrast, cynomolgus macaques of Mauritian origin have been reported to be relatively resistant to SHIV89.6P-induced CD4 + T-cell depletion (Reimann et al., 2005) . Our results are consistent with those for the rhesus model of SHIV infection in which CD4 + T cells were depleted throughout the observation T. Okamura and others period. Recovery of CD4 + T cells was not observed in those animals. Moreover, the proportion of CD4 + T cells was reduced in the lymphoid tissues of SHIV-infected macaques. Such profound CD4 + T-cell depletion in peripheral blood and lymphoid tissues might have caused the decline in SHIV-specific immune responses during the observation period. Moreover, the majority of SHIV89.6P-infected macaques eventually showed progression to AIDS symptoms. These animals showed severe CD4 + depletion in lymphoid tissues (1.1±0.8 %) (data not shown). These results are comparable to the results for the SHIV89.6P infection model of Indian rhesus macaques (Letvin et al., 2006; Wilson et al., 2006) .
Indian rhesus macaques that fail to show an immune response to SIV infection have rapid disease progression (Letvin et al., 2006; Ling et al., 2002; Wilson et al., 2006) . In the present study, eight macaques developed AIDS symptoms in 658-1626 days after SIV infection (Table 2) , indicating that progression to AIDS symptoms after SIV infection is slower in cynomolgus macaques than in Indian rhesus macaques. A previous study showed that SIV-specific cellular immune responses are important for both the control of SIV infection and the outcome of SIV disease (Karlsson et al., 2007) . In the present study, early and strong IFNg ELISPOT responses were observed in SIV-infected macaques. In these macaques, there was also less decline in the number of CD4 + T cells in peripheral blood during acute infection. Additionally, the proportion of CD4 + T cells was slightly lower than the normal level in lymphoid tissues of SIV-infected macaques. The IFN-g ELISPOT responses generated in those macaques after SIV infection were associated with better preservation of CD4 + T cells. These results indicate the importance of SIV-specific cellular immune responses during SIV infection for the control of disease progression in cynomolgus macaques.
In a previous study, in vitro passage of SIV in PBMCs derived from Chinese rhesus macaques resulted in an accelerated disease course when inoculated into Indian rhesus macaques, with higher levels of apoptosis occurring in lymph node tissues in Indian than in Chinese rhesus macaques. This #0027  #0030  #0032  #0033   #0034  #0035   #0036  #0038  #5041  #5043  #5045  #5047  #5048  #5046  #5044  #5042  #0039  #0037  #0031  #0029  8   7 Fig. 4 . Kinetics of plasma viral loads and CD4 + T cells in macaques after repeated intrarectal challenge with SIVmac239, SIVmac251 or SHIV89.6P. (a) Plasma viral load was assessed by using a real-time PCR system. A level less than 100 copies ml À1 was undetectable by this system. (b) Count of CD4 + T cells was analysed by flow cytometry and whole-blood cell counts. Left panels: in the SIVmac239-inoculated macaques, the 50 000, 5000 and 500 TCID 50 groups are denoted by red, black and blue lines, respectively. Middle panels: in the SIVmac251-inoculated macaques, the 3000, 300 and 30 TCID 50 groups are denoted by red, black and blue lines, respectively. Right panels: in the SHIV89.6P-inoculated macaques, the 50 000, 5000 and 500 TCID 50 groups are denoted by red, black and blue lines, respectively, and the 50 TCID 50 group is denoted by white squares. Arrows indicate sequential challenge times.
observation suggests that host factors, rather than the intrinsic properties of SIV, may be more important determinants when comparing the pathogenicity of SIVmac251 in Indian and Chinese rhesus macaques (Cumont et al., 2008) . In the present study, our viral stocks were prepared by passage in PBMCs derived from cynomolgus macaques. However, we did not determine whether these stocks were more pathogenic in cynomolgus macaques. Therefore, it is possible that disease progression might be suppressed by unknown host factors in cynomolgus macaques. Further studies are in progress to address the mechanisms involved in differences between the simian lentivirus-infected cynomolgus macaque and rhesus macaque AIDS models.
In the rhesus macaque mucosal model of SIV infection, repeated inoculation of a low dose of pathogenic SIV accurately reflects human sexual transmission (McDermott et al., 2004) . To establish a rectal infection model, we repeatedly challenged macaques intrarectally according to the strategy depicted in Table 3 . The mucosal infection doses were determined to be more than 5000, 300 and 500 TCID 50 for SIVmac239, SIVmac251 and SHIV89.6P, respectively. Moreover, all infected macaques elicited antibody and cellular immune responses. In contrast, macaques inoculated with a dose less than the above infectious doses of SIV or SHIV failed to show any evidence of infection, such as viral RNA detection and induction of immune responses. Our study demonstrated that these mucosal challenge models of cynomolgus macaques from different Asian countries may be valuable tools for the evaluation of candidate HIV vaccines and could offer a more physiologically relevant regimen for pathogenic SIV and SHIV infection experiments. Left panels: in the SIVmac239-inoculated macaques, the 50 000, 5000 and 500 TCID 50 groups are denoted by red, black and blue lines, respectively. Middle panels: in the SIVmac251-inoculated macaques, the 3000, 300 and 30 TCID 50 groups are denoted by red, black and blue lines, respectively. Right panels: in the SHIV89.6P-inoculated macaques, the 50 000, 5000 and 500 TCID 50 groups are denoted by red, black and blue lines, respectively, and the 50 TCID 50 group is denoted by white squares. Arrows indicate sequential challenge times. Cellular immune responses to SIV or SHIV in macaques after repeated intrarectal challenge with SIVmac239 (d), SIVmac251 (e) or SHIV89.6P (f). Number of SIV Gag-Pol-and SIV Env-or HIV Env-specific IFN-g-producing cells in cynomolgus macaque PBMCs at 12 weeks after repeated intrarectal challenge with SIVmac239, SIVmac251 or SHIV89.6P.
The rhesus macaque Trim5 gene is polymorphic, and the encoded protein includes a Trim5-cyclophiline (TrimCyp) in which CypA has replaced the Trim5a-binding domain (Brennan et al., 2008; Liao et al., 2007; Newman et al., 2008) . Since rhesus macaques co-expressing TrimCyp alleles could restrict SIVsm but not with SIVmac239 (Kirmaier et al., 2010) , it is reasonable to assume that the combination of Trim5a and TrimCyp functions more efficiently as an antiviral factor against SIVsm. Previous studies on a live attenuated SIV vaccine showed that the Trim5a genotype in Mauritian cynomolgus macaques had no impact on vaccine outcome for both homologous and heterologous SIV challenges; however, the effect of Trim5a on long-term viral control was not elucidated (Mattiuzzo et al., 2013) . Recently, Trim5 genotyping has been done in cynomolgus macaques from Indonesia, Malaysia and Philippines (Saito et al., 2012a) . Accordingly, we determined the Trim5 genotypes in all macaques used in this study (Tables 1 and  3 ). Further study is necessary to clarify the association of Trim5a alleles with SIVmac and SHIV replication.
Indian rhesus macaque AIDS models possessing MHC-I alleles, such as Mamu-A*01, Mamu-B*08 and Mamu-B*17, tend to show slower disease progression after SIVmac challenge (Loffredo et al., 2007; Moth e et al., 2003; Mühl et al., 2002; Yant et al., 2006) . Mauritian cynomolgus macaques have extremely limited MHC genetic diversity, with only seven major haplotypes and fewer than 30 MHC class I alleles . Among these, three common MHC haplotypes express Mafa-A*25 and Mafa-A*29. Indeed, 88 % of Mauritian cynomolgus macaques possess these alleles, and these animals mount three newly defined SIV-specific CD8 + T-cell epitopes that can select for SIV escape variants (Bimber et al., 2009; Wiseman et al., 2007) . In a previous study, although the MHC haplotype did not affect viral loads in Mauritian cynomolgus macaques challenged with SIVsmE660 (Berry et al., 2011) , animals possessing MHC haplotype H6 alleles had lower viral loads during the chronic phase of SIVmac251 challenge (Aarnink et al., 2011; Mee et al., 2009) . Therefore, analysis of the MHC allele is important for an HIV vaccine study using cynomolgus macaques. In a previous study, Saito et al. (2012b) successfully identified MHC class I alleles and haplotypes in cynomolgus macaques from Indonesia, Malaysia and Philippines. We therefore analysed the MHC class I alleles of the macaques used in this study. As shown in Tables 1 and 3 , the macaques had variable MHC class I alleles and we did not find restrictive MHC class I alleles in the animals used in this study that are similar to Mamu-A*01, Mamu-B*08 and Mamu-B*17 in rhesus macaques. Also, these alleles showed more genetic diversity than those of Mauritian cynomolgus macaques.
Overall, we demonstrated the pathogenesis of SIVmac and that of SHIV89.6P in cynomolgus macaques from Indonesia, Malaysia and Philippines in this study. A comparison of parameters including plasma viral loads, peripheral CD4 + T-cell counts, patterns of viral antigen-specific immune responses and disease outcomes showed that SIV and SHIV are pathogenic in cynomolgus macaques despite the different countries of origin. Compared to Indian rhesus macaques, cynomolgus macaques from Asian countries are equally permissive to various strains of SIVmac and SHIV, and they showed increased survival following SIV or SHIV infection, indicating that cynomolgus macaques can provide a model that is closer to the course of HIV-1 disease progression in humans. Taken together, these results indicate that the cynomolgus macaque immunodeficiency virus infection model is a useful tool for virus pathogenesis, vaccine and therapeutic studies in AIDS.
METHODS
Viruses. SIVmac239, SIVmac251 and SHIV89.6P were used in this study. SIVmac239 and SHIV89.6P stock viruses were propagated in PBMCs from cynomolgus macaques. Briefly, PBMCs were separated by a standard Ficoll density gradient separation method and cultured in RPMI1640 supplemented with 10 % fetal bovine serum, 2 mM L-glutamine and 100 units IL-2 ml À1 (Shionogi) and then stimulated with phytohaemmagglutinin for 72 h. The cells were infected with SIVmac239 or SHIV89.6P at an m.o.i. of 0.1. Half of the culture medium was replaced with a fresh culture medium every 3 days, and cell-free supernatants were collected between 6 and 9 days post-infection. The TCID 50 values of SIVmac239 and SHIV89.6P were measured using HSC-F and M8166 cell lines, respectively. The values of viral stocks were 5Â10 5 TCID 50 for SIVmac239 and 3Â10 5 TCID 50 for SHIV89.6P. SIVmac251 stocks (4Â10 4 TCID 50 ) were provided by Dr Igarashi (Institute for Virus Research, Kyoto University).
Animals and sample collection. We used 36 adult male cynomolgus macaques (from Indonesia, Philippines and Malaysia), all of which were negative for SIV, simian type D retrovirus, simian T-cell lymphotropic virus, simian foamy virus, Epstein-Barr virus, cytomegalovirus and B virus. Sixteen cynomolgus macaques were inoculated intravenously with pathogenic SIVmac239 and SHIV89.6P, four were inoculated intravenously with one TCID 50 of SIVmac239, seven were inoculated intravenously with 1000 TCID 50 of SIVmac239 and five were inoculated intravenously with 10 000 TCID 50 of SHIV89.6P (Table 1) (Budde et al., 2012; Nomura et al., 2012; Saito et al., 2014) . The times of death are shown in Table 2 . The rectal challenge protocol has been described previously (Greene et al., 2014; McDermott et al., 2004) . Six cynomolgus macaques in three groups were challenged intrarectally with up to five inoculations of 50 000, 5000 or 500 TCID 50 of SIVmac239. Six cynomolgus macaques in three groups were challenged intrarectally with up to five inoculations of 3000, 300 or 30 TCID 50 of SIVmac251. Eight cynomolgus macaques in four groups were challenged intrarectally with up to five inoculations of 50 000, 5000, 500 or 50 TCID 50 of SHIV89.6P (Table 3 ). The interval between inoculations was 1 week. Blood was collected periodically using sodium citrate as an anticoagulant, and used for determination of CD4 + T-cell counts, quantification of plasma viral loads and immunological analysis. Lymphoid tissue samples were obtained by biopsy at 34 weeks after virus infection and were used for determination of proviral DNA loads, CD4 + T-cell proportion and histopathology. These studies were performed in TPRC, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), after approval by the Committee on the Ethics of Animal Experiments of NIBIOHN in accordance with the guidelines for animal experiments at NIBIOHN. The animals were used under the supervision of the veterinarians in charge of the animal facility. The endpoint for the animals being killed was determined by typical clinical symptoms of AIDS such as weight loss, diarrhoea and neurological syndrome. These diagnostics were performed by the veterinarians.
MHC class I alleles. Total RNA was isolated from PBMCs of cynomolgus macaques using an RNeasy Mini Kit (Qiagen). Full-length cDNA samples for mafa class I genes were amplified by RT-PCR as described previously (Boyson et al., 1996) . Sequencing reactions were performed using a BigDye terminator cycle sequencing kit (Life Technology), and samples were run on an automated capillary sequencing system (ABI Genetic Analyzer 3130xl). The resulting sequences were analysed by the BLAT program of UCSC and were referred to the IMGT/ MHC Non-human Primate Immuno Polymorphism Database-MHC (IPD-MHC).
Trim5a genotypes. Total genomic DNA was extracted from PBMCs of cynomolgus macaques using a QIAamp DNA Mini Kit (Qiagen). Trim5 genotypes were determined by PCR as described previously (Saito et al., 2012a) .
Plasma viral RNA and proviral DNA loads. Viral RNA was prepared from cell-free plasma using a QIAamp Viral RNA Mini Kit (Qiagen) according to the manufacturer's protocol. A DNA sample was extracted directly from frozen lymphoid tissue of each macaque using a QIAamp DNA Mini Kit (Qiagen) according to the manufacturer's protocol. Viral loads in plasma and proviral DNA loads in lymphoid tissue were determined by quantitative RT-PCR and quantitative PCR, respectively, as described previously (Inaba et al., 2010; Mori et al., 2001 ).
CD4
+ T-cell counts. In total, 100 µl of whole blood from each of the cynomolgus macaques was stained with combinations of fluorescenceconjugated monoclonal antibodies: anti-CD3 (SP34-2; BD), anti-CD4 (L200; BD) and CD8 (DK25; Dako). Flow cytometric acquisition was performed on a FACSCanto II flow cytometer (BD). Data analysis was conducted using FACSDiVa software.
Immunohistochemistry. Lymphoid tissue samples were fixed in 4 % paraformaldehyde in PBS at 4 C overnight and embedded in paraffin wax. Sections were de-paraffinized by pretreatment with 0.5 % H 2 O 2 in methanol and then subjected to antigen retrieval with target retrieval solution (Dako S1700, pH 6.1) and heating in an autoclave for 20 min at 121 C. The sections were then incubated with an anti-human CD4 mouse monoclonal antibody (1 : 30; NCL-CD4; Novocastra Laboratories) or anti-SIV mouse monoclonal antibody (1 : 100; SIV-Nef; Santa Cruz Biotechnology) at 4 C for 24 h. Following brief washes with a buffer, the sections were incubated via the EnVision + Dual Link-HRP system (Dako) as a secondary stage for 60 min. Labelling was 'visualized' by treating the sections with chromogen 3-3' diaminobenzidine tetroxide (Dojin Kagaku) and H 2 O 2 . The sections were then counterstained with haematoxylin.
Virus-specific IFN-g ELISPOT assay. An ELISPOT assay was performed following the method developed at the Wisconsin University Primate Center (Moth e et al., 2002 (Moth e et al., , 2003 . Ninety-six-well, flat-bottom plates were coated with an anti-IFN-g monoclonal antibody (clone MD-1; U-Cytech) and blocked with 2 % BSA in PBS. PBMCs obtained at 16, 50 and 90 weeks after infection were co-cultured with autologous herpes virus papio-immortalized B-lymphoblastoid cell lines (B-LCL) infected with recombinant vaccinia virus expressing SIV Gag-Pol and SIV Env or HIV Env, respectively, for 12 h. Gold-labelled anti-biotin IgG solution (U-Cytech) was added to the washed plates, which were then incubated for 1 h at 37 C. Individual spot-forming cells (SFCs) were counted using the KS ELISPOT compact system (Zeiss) after a 15 min reaction with an activator mix (U-Cytech). An SFC was defined as a large black spot with a fuzzy border.
Virus-specific antibody titre. Anti-SHIV or SIV antibody titres were determined using a commercial passive agglutination method (Serodia-HIV1/2; Fuji Rebio). Isolated plasma samples were serially diluted and assayed. The antibody titre was measured by fourfold serial dilution of each sample, as recommended by the manufacturer.
